Journal Article
. 2021 May; 35(5):109071.
doi: 10.1016/j.celrep.2021.109071.

Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy

Nicholas C DeVito 1 Michael Sturdivant 1 Balamayooran Thievanthiran 1 Christine Xiao 1 Michael P Plebanek 1 April K S Salama 1 Georgia M Beasley 2 Alisha Holtzhausen 3 Veronica Novotny-Diermayr 4 John H Strickler 1 Brent A Hanks 5 
Affiliations
  • PMID: 33951424
  •     72 References
  •     5 citations

Abstract

While immune checkpoint blockade is associated with prolonged responses in multiple cancers, most patients still do not benefit from this therapeutic strategy. The Wnt-β-catenin pathway is associated with diminished T cell infiltration; however, activating mutations are rare, implicating a role for autocrine/paracrine Wnt ligand-driven signaling in immune evasion. In this study, we show that proximal mediators of the Wnt signaling pathway are associated with anti-PD-1 resistance, and pharmacologic inhibition of Wnt ligand signaling supports anti-PD-1 efficacy by reversing dendritic cell tolerization and the recruitment of granulocytic myeloid-derived suppressor cells in autochthonous tumor models. We further demonstrate that the inhibition of Wnt signaling promotes the development of a tumor microenvironment that is more conducive to favorable responses to checkpoint blockade in cancer patients. These findings support a rationale for Wnt ligand-focused treatment approaches in future immunotherapy clinical trials and suggest a strategy for selecting those tumors more responsive to Wnt inhibition.

Keywords: Wnt inhibition; Wnt-β-catenin pathway; anti-PD-1 resistance; dendritic cells; indoleamine 2,3-dioxygenase; melanoma; myeloid-deriver suppressor cells; non-small cell lung cancer; regulatory T cells; tumor immunotherapy.

Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity.
Yuan Hong, Indumathi Manoharan, +10 authors, Santhakumar Manicassamy.
Oncoimmunology, 2016 May 04; 5(4). PMID: 27141399    Free PMC article.
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.
Alexander J Muller, James B DuHadaway, +2 authors, George C Prendergast.
Nat Med, 2005 Feb 16; 11(3). PMID: 15711557
Highly Cited.
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase.
Michel DuPage, Alison L Dooley, Tyler Jacks.
Nat Protoc, 2009 Jun 30; 4(7). PMID: 19561589    Free PMC article.
Highly Cited.
Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.
Fei Zhao, Kathy Evans, +6 authors, Brent A Hanks.
Cancer Immunol Res, 2018 Sep 14; 6(12). PMID: 30209062    Free PMC article.
sFRP-2 is a target of the Wnt-4 signaling pathway in the developing metanephric kidney.
B Lescher, B Haenig, A Kispert.
Dev Dyn, 1998 Dec 16; 213(4). PMID: 9853965
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.
Alfonso R Sánchez-Paulete, Francisco J Cueto, +9 authors, Ignacio Melero.
Cancer Discov, 2015 Oct 24; 6(1). PMID: 26493961    Free PMC article.
Highly Cited.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas.
Cell, 2017 Feb 12; 168(4). PMID: 28187290    Free PMC article.
Highly Cited. Review.
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
Stefani Spranger, Daisy Dai, Brendan Horton, Thomas F Gajewski.
Cancer Cell, 2017 May 10; 31(5). PMID: 28486109    Free PMC article.
Highly Cited.
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
Balamayoora Theivanthiran, Kathy S Evans, +12 authors, Brent A Hanks.
J Clin Invest, 2020 Feb 06; 130(5). PMID: 32017708    Free PMC article.
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.
David H Munn, Andrew L Mellor.
Trends Immunol, 2016 Feb 04; 37(3). PMID: 26839260    Free PMC article.
Highly Cited. Review.
Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine.
Santhakumar Manicassamy, Boris Reizis, +4 authors, Bali Pulendran.
Science, 2010 Aug 14; 329(5993). PMID: 20705860    Free PMC article.
Highly Cited.
DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation.
Qian Xiao, Jibo Wu, +14 authors, Dianqing Wu.
Nat Med, 2018 Feb 13; 24(3). PMID: 29431745    Free PMC article.
Highly Cited.
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.
Rikke B Holmgaard, Dmitriy Zamarin, +5 authors, Jedd D Wolchok.
Cell Rep, 2015 Sep 29; 13(2). PMID: 26411680    Free PMC article.
Highly Cited.
Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex.
Youn-Sang Jung, Jae-Il Park.
Exp Mol Med, 2020 Feb 11; 52(2). PMID: 32037398    Free PMC article.
Review.
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Colin W Steele, Saadia A Karim, +23 authors, Jennifer P Morton.
Cancer Cell, 2016 Jun 07; 29(6). PMID: 27265504    Free PMC article.
Highly Cited.
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.
Douglas Marvel, Dmitry I Gabrilovich.
J Clin Invest, 2015 Jul 15; 125(9). PMID: 26168215    Free PMC article.
Highly Cited. Review.
Indoleamine 2,3-dioxygenase and tumor-induced tolerance.
David H Munn, Andrew L Mellor.
J Clin Invest, 2007 May 04; 117(5). PMID: 17476344    Free PMC article.
Highly Cited. Review.
Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice.
Bradford A Perez, A Paiman Ghafoori, +8 authors, David G Kirsch.
Front Oncol, 2013 Apr 09; 3. PMID: 23565506    Free PMC article.
Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
Moshe Sade-Feldman, Julia Kanterman, +6 authors, Michal Baniyash.
Clin Cancer Res, 2016 Nov 01; 22(23). PMID: 27178742
Highly Cited.
Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase.
Richard Metz, James B Duhadaway, +4 authors, George C Prendergast.
Mol Cancer Ther, 2010 Jun 10; 9(6). PMID: 20530717    Free PMC article.
Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.
Alisha Holtzhausen, Fei Zhao, +4 authors, Brent A Hanks.
Cancer Immunol Res, 2015 Jun 05; 3(9). PMID: 26041736    Free PMC article.
Highly Cited.
Secreted Frizzled-related Protein 2 (sFRP2) Redirects Non-canonical Wnt Signaling from Fz7 to Ror2 during Vertebrate Gastrulation.
Eva-Maria Brinkmann, Benjamin Mattes, +6 authors, Suat Özbek.
J Biol Chem, 2016 May 01; 291(26). PMID: 27129770    Free PMC article.
Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.
Z Shen, G Reznikoff, G Dranoff, K L Rock.
J Immunol, 1997 Mar 15; 158(6). PMID: 9058806
Highly Cited.
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting.
Belal Chaudhary, Eyad Elkord.
Vaccines (Basel), 2016 Aug 12; 4(3). PMID: 27509527    Free PMC article.
Highly Cited. Review.
Reporter gene HEK 293 cells and WNT/Frizzled fusion proteins as tools to study WNT signaling pathways.
Larisa Ring, Iris Peröbner, +3 authors, Alexander Faussner.
Biol Chem, 2011 Aug 26; 392(11). PMID: 21864196
A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma.
Tuomas Tammela, Francisco J Sanchez-Rivera, +15 authors, Tyler Jacks.
Nature, 2017 May 11; 545(7654). PMID: 28489818    Free PMC article.
Highly Cited.
Acquired Resistance to Immune Checkpoint Inhibitors.
Adam J Schoenfeld, Matthew D Hellmann.
Cancer Cell, 2020 Apr 15; 37(4). PMID: 32289269    Free PMC article.
Review.
Molecular basis for catalysis and substrate-mediated cellular stabilization of human tryptophan 2,3-dioxygenase.
Ariel Lewis-Ballester, Farhad Forouhar, +10 authors, Liang Tong.
Sci Rep, 2016 Oct 21; 6. PMID: 27762317    Free PMC article.
WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death.
Marcus M Fischer, Belinda Cancilla, +14 authors, Timothy Hoey.
Sci Adv, 2017 Jul 12; 3(6). PMID: 28691093    Free PMC article.
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, +15 authors, Roger S Lo.
Cell, 2016 Mar 22; 165(1). PMID: 26997480    Free PMC article.
Highly Cited.
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.
Jeffrey Weber, Geoffrey Gibney, +11 authors, Yian Ann Chen.
Cancer Immunol Res, 2016 Feb 14; 4(4). PMID: 26873574    Free PMC article.
Highly Cited.
Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.
K Inaba, M Inaba, +5 authors, R M Steinman.
J Exp Med, 1992 Dec 01; 176(6). PMID: 1460426    Free PMC article.
Highly Cited.
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
S Lindsey Davis, Dana B Cardin, +8 authors, Steven J Cohen.
Invest New Drugs, 2019 Jul 25; 38(3). PMID: 31338636    Free PMC article.
CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma.
O Mandelboim, G Berke, +3 authors, L Eisenbach.
Nature, 1994 May 05; 369(6475). PMID: 8164742
Wnt Signaling Cascade in Dendritic Cells and Regulation of Anti-tumor Immunity.
Amol Suryawanshi, Mohamed S Hussein, Puttur D Prasad, Santhakumar Manicassamy.
Front Immunol, 2020 Mar 07; 11. PMID: 32132993    Free PMC article.
Review.
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.
Austin Gurney, Fumiko Axelrod, +20 authors, Timothy Hoey.
Proc Natl Acad Sci U S A, 2012 Jul 04; 109(29). PMID: 22753465    Free PMC article.
Highly Cited.
SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment.
Y Sun, D Zhu, +4 authors, J Xu.
Oncogene, 2016 Jan 12; 35(33). PMID: 26751775    Free PMC article.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, +16 authors, KEYNOTE-024 Investigators.
N Engl J Med, 2016 Oct 11; 375(19). PMID: 27718847
Highly Cited.
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Tuba N Gide, James S Wilmott, Richard A Scolyer, Georgina V Long.
Clin Cancer Res, 2017 Nov 12; 24(6). PMID: 29127120
Review.
Deletion of Atm in Tumor but not Endothelial Cells Improves Radiation Response in a Primary Mouse Model of Lung Adenocarcinoma.
Jordan A Torok, Patrick Oh, +5 authors, David G Kirsch.
Cancer Res, 2018 Oct 14; 79(4). PMID: 30315114    Free PMC article.
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
Jason J Luke, Riyue Bao, +2 authors, Thomas F Gajewski.
Clin Cancer Res, 2019 Jan 13; 25(10). PMID: 30635339    Free PMC article.
Highly Cited.
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors.
Nithya Krishnamurthy, Razelle Kurzrock.
Cancer Treat Rev, 2017 Nov 24; 62. PMID: 29169144    Free PMC article.
Highly Cited. Review.
PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers.
Zheng Zhong, Sugunavathi Sepramaniam, +4 authors, David M Virshup.
Oncogene, 2019 Aug 09; 38(40). PMID: 31391551
Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, +25 authors, KEYNOTE-001 Investigators.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891174
Highly Cited.
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
Alexander J Muller, Mark G Manfredi, Yousef Zakharia, George C Prendergast.
Semin Immunopathol, 2018 Sep 12; 41(1). PMID: 30203227
Highly Cited. Review.
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Georgina V Long, Reinhard Dummer, +15 authors, Tara C Mitchell.
Lancet Oncol, 2019 Jun 22; 20(8). PMID: 31221619
Highly Cited.
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.
Bernhard Mlecnik, Gabriela Bindea, +29 authors, Jérôme Galon.
Immunity, 2016 Mar 18; 44(3). PMID: 26982367
Highly Cited.
CXCL5 as Regulator of Neutrophil Function in Cutaneous Melanoma.
Agnes Forsthuber, Katharina Lipp, +6 authors, Robert Loewe.
J Invest Dermatol, 2018 Jul 17; 139(1). PMID: 30009831
Wnt/β-catenin signaling and disease.
Hans Clevers, Roel Nusse.
Cell, 2012 Jun 12; 149(6). PMID: 22682243
Highly Cited. Review.
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.
Rebekka Weber, Viktor Fleming, +5 authors, Viktor Umansky.
Front Immunol, 2018 Jun 27; 9. PMID: 29942309    Free PMC article.
Highly Cited. Review.
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
Steven L Highfill, Yongzhi Cui, +5 authors, Crystal L Mackall.
Sci Transl Med, 2014 May 23; 6(237). PMID: 24848257    Free PMC article.
Highly Cited.
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.
Christina Pfirschke, Camilla Engblom, +18 authors, Mikael J Pittet.
Immunity, 2016 Feb 14; 44(2). PMID: 26872698    Free PMC article.
Highly Cited.
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.
William E Damsky, David P Curley, +8 authors, Marcus Bosenberg.
Cancer Cell, 2011 Dec 17; 20(6). PMID: 22172720    Free PMC article.
Highly Cited.
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
De-Yan Hou, Alexander J Muller, +6 authors, David H Munn.
Cancer Res, 2007 Jan 20; 67(2). PMID: 17234791
Highly Cited.
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Kathleen N Moore, Camille C Gunderson, +9 authors, Roisin E O'Cearbhaill.
Gynecol Oncol, 2019 Jun 09; 154(2). PMID: 31174889    Free PMC article.
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.
Antonio Jimeno, Michael Gordon, +9 authors, David C Smith.
Clin Cancer Res, 2017 Sep 29; 23(24). PMID: 28954784
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, +20 authors, KEYNOTE-006 investigators.
N Engl J Med, 2015 Apr 22; 372(26). PMID: 25891173
Highly Cited.
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
Hélène Salmon, Juliana Idoyaga, +19 authors, Miriam Merad.
Immunity, 2016 Apr 21; 44(4). PMID: 27096321    Free PMC article.
Highly Cited.
Discovery of IDO1 Inhibitors: From Bench to Bedside.
George C Prendergast, William P Malachowski, James B DuHadaway, Alexander J Muller.
Cancer Res, 2017 Dec 17; 77(24). PMID: 29247038    Free PMC article.
Highly Cited. Review.
Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation.
Xiaofeng Li, Peng Liu, +11 authors, Dianqing Wu.
Nat Genet, 2005 Aug 02; 37(9). PMID: 16056226
Highly Cited.
β-catenin promotes regulatory T-cell responses in tumors by inducing vitamin A metabolism in dendritic cells.
Yuan Hong, Indumathi Manoharan, +7 authors, Santhakumar Manicassamy.
Cancer Res, 2015 Jan 09; 75(4). PMID: 25568183    Free PMC article.
Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization.
Fei Zhao, Christine Xiao, +9 authors, Brent A Hanks.
Immunity, 2018 Jan 19; 48(1). PMID: 29343435    Free PMC article.
Highly Cited.
A role of Pygopus as an anti-repressor in facilitating Wnt-dependent transcription.
Juliusz Mieszczanek, Marc de la Roche, Mariann Bienz.
Proc Natl Acad Sci U S A, 2008 Nov 28; 105(49). PMID: 19036929    Free PMC article.
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
Stefani Spranger, Riyue Bao, Thomas F Gajewski.
Nature, 2015 May 15; 523(7559). PMID: 25970248
Highly Cited.
Blocking IDO activity to enhance anti-tumor immunity.
David H Munn.
Front Biosci (Elite Ed), 2011 Dec 29; 4(2). PMID: 22201909
Review.
WNT signaling pathway and stem cell signaling network.
Masuko Katoh, Masaru Katoh.
Clin Cancer Res, 2007 Jul 20; 13(14). PMID: 17634527
Highly Cited. Review.
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
Christiane Meyer, Laurène Cagnon, +6 authors, Daniel E Speiser.
Cancer Immunol Immunother, 2013 Dec 21; 63(3). PMID: 24357148
Highly Cited.
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Omid Hamid, Henrik Schmidt, +9 authors, David Berman.
J Transl Med, 2011 Nov 30; 9. PMID: 22123319    Free PMC article.
Highly Cited.
Induction of pulmonary indoleamine 2,3-dioxygenase by interferon.
R Yoshida, J Imanishi, +2 authors, O Hayaishi.
Proc Natl Acad Sci U S A, 1981 Jan 01; 78(1). PMID: 6165986    Free PMC article.
Highly Cited.
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Christopher S Garris, Sean P Arlauckas, +20 authors, Mikael J Pittet.
Immunity, 2018 Dec 16; 49(6). PMID: 30552023    Free PMC article.
Highly Cited.
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.
Shetal A Patel, Andy J Minn.
Immunity, 2018 Mar 22; 48(3). PMID: 29562193    Free PMC article.
Highly Cited. Review.
Pharmacologically Targeting the WNT/β-Catenin Signaling Cascade: Avoiding the Sword of Damocles.
Keane K Y Lai, Michael Kahn.
Handb Exp Pharmacol, 2021 Sep 01; 269. PMID: 34463849
Development and Validation of Tumor Immunogenicity Based Gene Signature for Skin Cancer Risk Stratification.
Maryam Yavartanoo, Gwan-Su Yi.
Int J Mol Sci, 2021 Nov 14; 22(21). PMID: 34769455    Free PMC article.
The Metabolic Control of Myeloid Cells in the Tumor Microenvironment.
Eloise Ramel, Sebastian Lillo, +3 authors, Maya Saleh.
Cells, 2021 Nov 28; 10(11). PMID: 34831183    Free PMC article.
Review.
Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.
Xueyan Li, Jiahui Zhong, +5 authors, Changjun Wang.
Front Immunol, 2022 Jan 11; 12. PMID: 35003065    Free PMC article.
Review.
Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review.
Szonja Anna Kovács, Balázs Győrffy.
J Transl Med, 2022 Jun 02; 20(1). PMID: 35641998
Systematic Review.